drugset

drugset / Trial / NCT07051603

SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population

NCT07051603 ↗

Phase 1 Recruiting 82 enrolled Shenzhen Salubris Pharmaceuticals Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability pharmacokinetics and pharmacodynamics of SAL0140 healthy Chinese population.

Timeline

Start: 2025-06-09
Primary completion: 2026-01
Completion: 2026-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SAL0140	Unknown	—	Oral

Indications